Relevant and useful manufacturer-sponsored support programs and resources can help drive collaborative and strategic partnerships with Integrated Delivery Network (IDN) customers. HIRC's report, Integrated Delivery Networks: Evaluation of Pharmaceutical Manufacturer Programs and Support Offerings, provides IDN ratings of manufacturer resources, examines the most valuable programs being offered, and identifies opportunities for future support. The report addresses the following:

• Which pharmaceutical firms receive the greatest number of "most valuable" program/resource nominations across 10 priority therapeutic areas? What are some examples of the most valuable programs in key disease areas?
• How do 30+ manufacturers rate in presence and overall value of programs/resources?
• How often are IDNs interacting with manufacturers and their programs/resource offerings based on their role/responsibility type?
• How often are 30+ manufacturers providing support to their key accounts across eight unique program types?
• What program opportunities exist to better meet the current needs of IDN customers?

Key Finding: Patient-centered resources (i.e., patient education, financial assistance) are highly regarded by IDN customers and should be a core offering for any new branded therapy; offerings that support population health and health equity can set manufacturers apart as true partners.

Pfizer Leads in Most Valuable Program/Resource Offerings for IDN Accounts. IDN executives were asked to consider and nominate a manufacturer-sponsored program or resource offering that has provided the most value across 10 broad disease areas. Pfizer receives the greatest number of “most valuable” program/resource nominations, followed by GSK and Novo Nordisk. Nominations were most often provided for patient-centered resources supporting vaccines, diabetes, and cardiovascular diseases.

The full report provides the full listing of 103 nominations received for 25 pharmaceutical firms and across 10 disease states.

Benchmarking 30+ Manufacturers in IDN Programs/Resources Engagement. For a listing of over 30 companies active in IDN engagement, HIRC reviews the programs/resources support landscape across three key metrics: 1) Presence (IDN has had experience with a manufacturer's program/resource in the last 12-18 months, 2) IDN ratings of firm's Value of Programs & Resources, and 3) Program Engagement across 8 unique program types. A handful of manufacturers are consistently positioning resources and programs with their IDN target accounts across multiple program categories.

Programs support benchmarks span the following eight program types and 10 broad therapeutic areas:

Therapeutic Areas Covered:

• Airway Diseases
• Behavioral Health
• Cardiovascular Disease
• Diabetes
• Inflammation & Immunology
• Neurological Diseases
• Oncology/Cancer
• Ophthalmology
• Rare Disease
• Vaccines

Program/Resource Types Covered:

• Access/Reimbursement Support
• Clinical Staff Training/Education
• Data Analytics/Insights
• Digital Engagement/Telehealth Support
• Medication Adherence Support
• Patient/Caregiver Education
• Population Health Management Support
• Social Determinants of Health/Health Equity Support

Research Methodology and Report Availability. In August, HIRC surveyed 56 pharmacy directors, medical directors, and quality/population health personnel from IDNs ranging in size and geographic location. The full report, Integrated Delivery Networks: Evaluation of Pharmaceutical Manufacturer Programs and Support Offerings, is part of the Organized Providers Service, and is now available to subscribers at www.hirc.com.